Biallelic and monoallelic mutations in B2M have been previously associated in single patients with primary [16] and secondary [17] resistance to anti-PD-1/PD-L1 in MSI-H/dMMR CRC, respectively, although a larger series has shown the opposite [23]. This evidence concerns the gene B2M and colorectal carcinoma.